BNTX
BioNTech SE
BNTX lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BNTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Strong | |
| Strong |
BNTX's cash flow and balance sheet are currently strong, but its revenue and profitability are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BNTX PE Valuation
BNTX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BNTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect BNTX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BNTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$7.48 | -$5.88 |
| Q1 2026 | -$5.65 | -$2.03 |
| Q4 2025 | -$5.20 | -$2.05 |
| Q3 2025 | -$2.63 | -$0.32 |
| Q2 2025 | -$1.60 | +$0.84 |
| Q1 2025 | -$3.62 | -854% |
| Q4 2024 | -$3.15 | -175% |
| Q3 2024 | -$2.31 | -119% |
BNTX lost $7.48 per share over the past year, and its loss has widened in each of the last four quarters.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over BNTX on earnings, with more consistent year-over-year improvement.
BNTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $117.3M | -60% |
| Q1 2026 | $133.4M | -34% |
| Q4 2025 | $998.6M | -24% |
| Q3 2025 | $1.7B | +22% |
| Q2 2025 | $289.7M | +103% |
| Q1 2025 | $203.1M | -2.6% |
| Q4 2024 | $1.3B | -20% |
| Q3 2024 | $1.4B | +39% |
BNTX's revenue has slid since its 2022 peak: $117M last quarter, down 60% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -898% | -706 points |
| Q1 2026 | -560% | -268 points |
| Q4 2025 | -26% | -38 points |
| Q3 2025 | -3.1% | -3.9 points |
| Q2 2025 | -192% | +559 points |
| Q1 2025 | -292% | -22 points |
| Q4 2024 | 12% | -23 points |
| Q3 2024 | 0.8% | -7.3 points |
BNTX's operating margin was −898% last quarter, down 706 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BNTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BNTX on profitability, with a higher operating margin.
BNTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$49.8M | -106% |
| Q1 2026 | -$539.5M | +$1.1B |
| Q4 2025 | $264M | +$932.4M |
| Q3 2025 | $901.1M | +$1.8B |
| Q2 2025 | $777.7M | -56% |
| Q1 2025 | -$1.6B | -$1.1B |
| Q4 2024 | -$668.4M | -153% |
| Q3 2024 | -$865.1M | -218% |
BNTX's free cash flow has turned positive again: $576M over the past year, against −$2.4B the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BNTX on cash flow, with more consistent year-over-year improvement.
BNTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +449K shares |
| 1 year | +4.8% | +11.7M shares |
| 3 years | +5.7% | +13.6M shares |
| 5 years | -2.1% | -5.5M shares |
| Available history | +10% | +23.9M shares |
BNTX has 253M diluted shares, up 4.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $146.7M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BNTX spent $147M buying back its own shares over the past year, after none the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BNTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BNTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -149.4x | Net Cash |
| Q4 2023 | -10.3x | Net Cash |
| Q3 2023 | -3.4x | Net Cash |
| Q2 2023 | -2.3x | Net Cash |
| Q1 2023 | -1.5x | Net Cash |
| Q4 2022 | -1.0x | Net Cash |
| Q3 2022 | -0.9x | Net Cash |
| Q2 2022 | -0.5x | Net Cash |
BNTX has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BNTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.6 | Neutral |
| Stochastic | 5.7 | Oversold |
BNTX's weekly RSI is 41 (neutral) and its Stochastic is 6 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BNTX PE vs Healthcare Sector
| Metric | BNTX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BNTX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BNTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $91.1 | 6.7% below |
| 20 week MA | $94.6 | 10% below |
| 50 week MA | $96.6 | 12% below |
| 100 week MA | $101.4 | 16% below |
| 200 week MA | $103.6 | 18% below |
BNTX is in a downtrend: it's below all five of its weekly moving averages, and 18% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BNTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.6 | $97.0 | +198% |
| 2021 | $97.0 | $255.3 | +163% |
| 2022 | $255.3 | $176.0 | -31% |
| 2023 | $176.0 | $105.5 | -40% |
| 2024 | $105.5 | $114.0 | +8% |
| 2025 | $114.0 | $94.5 | -17% |
| 2026 YTD | $94.5 | $85.0 | -10% |
BNTX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.